Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.71 USD

28.71
28,634,708

-0.17 (-0.59%)

Updated Aug 15, 2024 04:01 PM ET

Pre-Market: $28.63 -0.08 (-0.28%) 8:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down

Merck & Co., Inc. (MRK) reported fourth-quarter 2016 earnings of 89 cents per share, which beat the Zacks Consensus Estimate of 88 cents by a penny.

    Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN

    How will these two drug stocks, MRK & AMGN, which are both scheduled to report Q4 results on Feb 2, fare this earnings season?

      Merck Keytruda Gets EU Approval for First-Line Lung Cancer

      Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.

        SanofiRegeneron Sarilumab Approved in Canada for Arthritis

        Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).

          Mark Vickery headshot

          Trade War Concerns Coming Home to Roost

          It hadn't been priced in at all during the Trump Rally, but now fears of a trade war with China and Mexico are being actualized.

            Kinjel Shah headshot

            Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft

            Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.

              Pfizer (PFE) Misses on Q4 Earnings; Tops Sales Estimate

              PFE missed fourth quarter earnings which came in at 47 cents while our consensus called for EPS of 50 cents.

                Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug

                Pfizer Inc. (PFE) announced that Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company's marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz.

                  Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE

                  Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.

                    Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study

                    Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.

                      Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?

                      We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.

                        Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?

                        We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint

                          Key highlights this week include earnings reports from companies like Bristol-Myers (BMY) as well as the J&J-Actelion deal.

                            Sheraz Mian headshot

                            Earnings Growth Returns, Will it Continue?

                            Corporate earnings have started growing again.

                              Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales

                              Bristol-Myers (BMY) reported fourth quarter earnings of 63 cents on revenues of $5.23 billion.

                                What Lies in Store for Pfizer (PFE) this Earnings Season?

                                Pfizer Inc. (PFE) will be reporting fourth-quarter and full-year 2016 earnings results on Jan 31, before market open.

                                  J&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit

                                  Johnson & Johnson (JNJ) reported a mixed quarter with earnings beating expectations while sales missing the same.

                                    Sweta Killa headshot

                                    Can Q4 Earnings Revitalize Healthcare ETFs?

                                    The Q4 earnings could bring some near-term relief given that the sector is expected to post earnings growth of 2.9% and revenue growth of 5.6%.

                                      Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval

                                      Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment.

                                        Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout

                                        Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.

                                          Sheraz Mian headshot

                                          Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works

                                          Today's Research Daily features new research reports on 16 major stocks, including Gilead Sciences (GILD), Las Vegas Sands (LVS) and Illinois Tool Works (ITW).

                                            What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?

                                            Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.

                                              Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended

                                              Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).

                                                ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

                                                On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).

                                                  Sweta Killa headshot

                                                  Trump Attacks Biotech & Pharma: ETFs Bleed

                                                  Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.